Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
August 07, 2024 16:05 ET
|
Alector, Inc.
Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer’s disease (AD) on track for Q4 2024 Patient baseline characteristics data for the INVOKE-2 trial confirm the...
Alector to Host Mid-Year Earnings Conference Call
July 31, 2024 16:05 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a...
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
July 28, 2024 08:05 ET
|
Alector, Inc.
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)-- ...
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
July 23, 2024 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations...
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 20, 2024 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
June 10, 2024 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANSISCO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host...
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
Alector to Participate in Upcoming Healthcare Conferences
May 09, 2024 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:05 ET
|
Alector, Inc.
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease, on track for Q4 2024 Strengthened leadership team with key appointments:...
Alector to Participate in Upcoming Healthcare Conferences
February 28, 2024 07:00 ET
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...